Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | NPY4R | P50391 | 9/20 | 0.48 |
| ▸ | NPY1R | P25929 | 6/20 | 0.48 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | CPA1 | P15085 | 2/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14509064 | 0.94 | NPY4R (0.50) | FOLH1GNPATNPY4RNPY1RNPY2R | |
| SCHEMBL14509070 | 0.94 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL14531425 | 0.91 | FOLH1 (0.49) | FOLH1GNPATNPY4RNPY1RNPY2R | |
| SCHEMBL14509077 | 0.90 | FNTA (0.49) | GNPATNPY4RMMEACECPA1 | |
| SCHEMBL14509094 | 0.86 | NPY4R (0.60) | FOLH1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL14531792 | 0.86 | NPY4R (0.60) | FOLH1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL14531426 | 0.84 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL14509071 | 0.84 | KISS1R (0.51) | FOLH1GNPATNPY4RNPY1RNPY2R | |
| SCHEMBL14509078 | 0.84 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL14509086 | 0.84 | GNPAT (0.48) | FOLH1GNPATNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105783-A1 | Process for the manufacture of peptide facilitators of reverse cholesterol transport | SIRCAR JAGADISH C | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105783-A1 | Process for the manufacture of peptide facilitators of reverse cholesterol transport | CETP, NPC1L1, SLC10A1 | FOLH1 789/4885GNPAT 1081/4885NPY4R 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.